Kineta Press Release Archives

Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 11, 2022 by Kineta Inc
Kineta Presented New Preclinical Data on its Anti-CD27 Agonist Antibody Program at the ESMO Immuno-oncology Congress 2021
December 17, 2021 by Kineta Inc
Kineta Presents Phase 1/2 Clinical Trial Design of KVA12.1 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 29, 2021 by Kineta Inc
Kineta Presented Compelling Preclinical Data on its New CD27 Antibody Program at the 2021 SITC Annual Meeting
November 16, 2021 by Kineta Inc
Kineta Presents Preclinical Data on its New CD27 Program at the AACR Conference on Tumor Immunology and Immunotherapy
October 7, 2021 by Kineta Inc
Kineta Announces Poster Presentation at the 2021 American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
September 28, 2021 by Kineta Inc
Kineta Announces Participation at H.C. Wainwright 23rd Annual Global Investment Conference
September 25, 2021 by Kineta Inc
Kineta Announces Patent Issuance of U.S. Patent for Composition of Matter of KCP506
August 10, 2021 by Kineta Inc
Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KVA12.1
July 27, 2021 by Kineta Inc
Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody
July 20, 2021 by Kineta Inc
Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506
July 14, 2021 by Kineta Inc
Kineta’s Thierry Guillaudeux Participated on Multiple Panel Presentations During Virtual Symposium on VISTA
June 24, 2021 by Kineta Inc
Kineta to Participate in “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond” Virtual Symposium
June 7, 2021 by Kineta Inc
Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021
April 12, 2021 by Kineta Inc
Kineta Presents Clinical Study Results of LHF-535 at the International Conference on Antiviral Research (ICAR)
March 25, 2021 by Kineta Inc
Kineta Presenting at Multiple Investor Conferences in March 2021
March 3, 2021 by Kineta Inc
Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic Pain
December 15, 2020 by Kineta Inc
Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies
December 9, 2020 by Kineta Inc
Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies
November 12, 2020 by Kineta Inc
Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Special Conference on Tumor Immunology and Immunotherapy
October 20, 2020 by Kineta Inc
Kineta to Extend Research Collaboration with Genentech to Develop a Novel Non-Opioid
October 8, 2020 by Kineta Inc
Kineta to Participate in BIO Investor Forum Digital
October 2, 2020 by Kineta Inc
Kineta to Present at September 2020 Virtual Investor Conferences
September 11, 2020 by Kineta Inc
Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506
August 12, 2020 by Kineta Inc
Kineta Invited to Present at August 2020 Investor Conferences
July 30, 2020 by Kineta Inc
Kineta to Present at July 2020 Virtual Investor Events
July 3, 2020 by Kineta Inc
Kineta Closes Investment Round to Advance Early Preclinical Development of Immuno-oncology Programs
May 5, 2020 by Kineta Inc
Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board
April 21, 2020 by Kineta Inc
Kineta to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
March 25, 2020 by Kineta Inc
Kineta Invited to Participate at the Opal Group’s Family Office Winter Forum in New York
February 28, 2020 by Kineta Inc
Kineta Invited to Participate at the Cowen and Company 40th Annual Health Care Conference
February 27, 2020 by Kineta Inc
Kineta Invited to Participate at the BIO CEO & Investor Conference
February 5, 2020 by Kineta Inc
Kineta Invited to Participate at the 2nd Annual Evercore ISI HealthCONx Conference
November 26, 2019 by Kineta Inc
Kineta Invited to Participate at October 2019 Investor Conferences
October 7, 2019 by Kineta Inc
Kineta Invited to Participate at the H.C. Wainwright 21st Annual Global Investment Conference
August 29, 2019 by Kineta Inc
Kineta Invited to Participate at Solebury Trout’s 9th Annual CEO Roundtable Conference
August 12, 2019 by Kineta Inc
Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535
August 6, 2019 by Kineta Inc
Kineta Secures NIAID Grant Worth Up to $5.8M to Evaluate LHF-535 in Arenaviruses
July 15, 2019 by Kineta Inc
Kineta Invited to Participate at the Oppenheimer Summit for Emerging Life Sciences Conference
May 28, 2019 by Kineta Inc
Kineta Invited to Present at the 2019 Life Science Innovation Northwest Conference
March 29, 2019 by Kineta Inc
Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies
December 17, 2018 by Kineta Inc
Kineta Initiates First-in-Human Clinical Trial of LHF-535 a Novel Therapy for Lassa Fever
September 5, 2018 by Kineta Inc
Kineta to Collaborate on the Development of a Novel Non-Opioid Pain Therapy with Genentech
April 16, 2018 by Kineta Inc
Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models
April 5, 2018 by Kineta Inc
Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference
March 23, 2018 by Kineta Inc
Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference
January 22, 2018 by Kineta Inc
Kineta Appoints Michael Banks as New Chief Financial Officer
January 2, 2018 by Kineta Inc
Kineta to Present at Symposium on Pandemic Preparedness
June 12, 2017 by Kineta Inc
Kineta to Present at Symposium on Next-Generation Therapeutics for the Treatment of Pain
April 25, 2017 by Kineta Inc
Kineta to Present at the Planet MicroCap Showcase 2017
April 21, 2017 by Kineta Inc
Kineta to Present at the 24th Annual Future Leaders in the Biotech Industry Conference
April 4, 2017 by Kineta Inc
Kineta RLR Agonist Demonstrates Tumor Regression and an Adaptive Immune Response in Colon Carcinoma Model
March 23, 2017 by Kineta Inc
KCP-400 Relieves Chronic Pain and Demonstrates Disease Modifying Effects
February 22, 2017 by Kineta Inc
Kineta to Present at Biotech Showcase Investor Conference during JP Morgan Week in San Francisco
January 6, 2017 by Kineta Inc
Kineta CEO to Speak on Immuno-oncology Panel at the BIO Investor Forum
October 31, 2016 by Kineta Inc
Kineta CEO Unveils its Immuno-oncology Program at the BIO Investor Forum
October 19, 2016 by Kineta Inc
UPDATE: Kineta Secures Funding to Expand Testing of Broad Spectrum Antivirals Against Zika Virus UPDATE
August 18, 2016 by Kineta Inc
Kineta Secures NIAID Funding to Expand Testing of Immune Modulators
July 31, 2016 by Kineta Inc
Kineta Presents Promising New Vaccine Adjuvant Data at American Association of Immunologists Annual Meeting
May 16, 2016 by Kineta Inc
Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials
May 5, 2016 by Kineta Inc
Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals
April 22, 2016 by Kineta Inc
Kineta Announces Promising New Data for KIN 1148 – a Novel Vaccine Adjuvant for Highly Pathogenic Flu
March 31, 2016 by Kineta Inc
Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress
March 22, 2016 by Kineta Inc